| scholarly article | Q13442814 |
| P2093 | author name string | Darshan J Dave | |
| P2860 | cites work | Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes | Q24642503 |
| Saxagliptin | Q28259979 | ||
| Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy | Q29620534 | ||
| Role of saxagliptin as monotherapy or adjunct therapy in the treatment of type 2 diabetes | Q33886865 | ||
| Saxagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus | Q34239784 | ||
| The role for saxagliptin within the management of type 2 diabetes mellitus: an update from the 2010 European Association for the Study of Diabetes (EASD) 46th annual meeting and the American Diabetes Association (ADA) 70th scientific session | Q34486000 | ||
| The biology of incretin hormones | Q34499706 | ||
| The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone | Q34608300 | ||
| Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial | Q34610019 | ||
| Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone | Q34613240 | ||
| Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis | Q34634794 | ||
| Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of action | Q36751470 | ||
| Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus | Q37141727 | ||
| Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus. | Q37426390 | ||
| Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes | Q37483511 | ||
| Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control | Q37621774 | ||
| Role of the incretin pathway in the pathogenesis of type 2 diabetes mellitus | Q37642377 | ||
| Incretin-based therapies in the management of type 2 diabetes: rationale and reality in a managed care setting | Q37784489 | ||
| Type 2 diabetes comorbidities and treatment challenges: rationale for DPP-4 inhibitors | Q42171281 | ||
| Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial | Q42905727 | ||
| Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus | Q42914097 | ||
| Saxagliptin and metformin XR combination therapy provides glycemic control over 24 hours in patients with T2DM inadequately controlled with metformin | Q42922274 | ||
| Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes | Q43299560 | ||
| Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. | Q45974567 | ||
| Pharmacokinetics of the dipeptidyl peptidase 4 inhibitor saxagliptin in rats, dogs, and monkeys and clinical projections | Q46104712 | ||
| Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes | Q46691051 | ||
| Thiazolidinediones and Heart Failure: A teleo-analysis | Q57413498 | ||
| A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results | Q69929000 | ||
| Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment | Q83438677 | ||
| Saxagliptin (Onglyza) for type 2 diabetes | Q84849347 | ||
| P433 | issue | 4 | |
| P921 | main subject | type 2 diabetes | Q3025883 |
| P304 | page(s) | 230-235 | |
| P577 | publication date | 2011-10-01 | |
| P1433 | published in | Journal of Pharmacology & Pharmacotherapeutics | Q15816637 |
| P1476 | title | Saxagliptin: A dipeptidyl peptidase-4 inhibitor in the treatment of type 2 diabetes mellitus | |
| P478 | volume | 2 |
| Q38546981 | Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus |
| Q27026211 | Clinical utility in the treatment of type 2 diabetes with the saxagliptin/metformin fixed combination |
| Q47699621 | Dipeptidyl Peptidase-4 Inhibition With Saxagliptin Ameliorates Angiotensin II-Induced Cardiac Diastolic Dysfunction in Male Mice |
| Q37551483 | Efficacy and safety of add on therapy of bromocriptine with metformin in Indian patients with type 2 diabetes mellitus: a randomized open labeled phase IV clinical trial |
| Q92936148 | Efficient New Protocols for Converting Primary Amides into Nitriles Initiated by P(NMe2)3, PCl3, or P(OPh)3 |
| Q95853584 | Simultaneous Estimation of Saxagliptin and Dapagliflozin in Human Plasma by Validated High Performance Liquid Chromatography - Ultraviolet Method |
Search more.